Asuragen, Inc. Announces Launch of Xpansion Interpreter™, a Service for AGG Mapping of the Fragile X Gene, in its CAP Accredited CLIA Laboratory

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen announced today the launch of Xpansion Interpreter™ through the Asuragen Clinical Services Laboratory. Xpansion Interpreter is the first clinically available service for definitively determining the number and location of AGG interruptions associated with expansion of the Fragile X gene, and it enables a better understanding of an individual’s risk of having a child with Fragile X syndrome. The availability of this information further enhances genetic counseling of women undergoing carrier testing for Fragile X syndrome.

Back to news